Stephanie Davis
Stock Analyst at Barclays
(0.87)
# 3,806
Out of 4,896 analysts
95
Total ratings
36.76%
Success rate
-109.1%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $175 → $185 | $168.53 | +9.77% | 5 | Apr 23, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $37.54 | +19.87% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $12.64 | -60.43% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $60.25 | +24.49% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $4.50 | +55.56% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.76 | +26.18% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $11.15 | +70.40% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $295.45 | -1.84% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $21.12 | +13.64% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $161.22 | -17.50% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $28.77 | +101.60% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $2.66 | +12.78% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $248.90 | +0.04% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $26.97 | +7.53% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $8.31 | +309.15% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $23.19 | +46.61% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $274.48 | -15.11% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $3.91 | +334.78% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $93.85 | -19.02% | 5 | Jun 7, 2022 |
Quest Diagnostics
Apr 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $185
Current: $168.53
Upside: +9.77%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $37.54
Upside: +19.87%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $12.64
Upside: -60.43%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $60.25
Upside: +24.49%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $4.50
Upside: +55.56%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.76
Upside: +26.18%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $11.15
Upside: +70.40%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $295.45
Upside: -1.84%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $21.12
Upside: +13.64%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $161.22
Upside: -17.50%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $28.77
Upside: +101.60%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.66
Upside: +12.78%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $248.90
Upside: +0.04%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $26.97
Upside: +7.53%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $8.31
Upside: +309.15%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $23.19
Upside: +46.61%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $274.48
Upside: -15.11%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $3.91
Upside: +334.78%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $93.85
Upside: -19.02%